文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

治疗性血浆置换对脓毒症诱导器官功能障碍危重成人患者短期死亡率的影响:系统评价与荟萃分析

Influence of therapeutic plasma exchange treatment on short-term mortality of critically ill adult patients with sepsis-induced organ dysfunction: a systematic review and meta-analysis.
PubMed 文献 · Crit Care · 2024-01-04
一句话结论辅助治疗性血浆置换可能降低脓毒症诱导器官功能障碍危重成人短期死亡率(RR 0.59),但作者认为广泛推广前需大型设计良好的随机试验。

该系统评价检索Medline、Embase、Cochrane图书馆和clinicaltrial.gov(1966年1月1日至2022年10月1日),纳入5项随机对照试验(n=367)和15项匹配队列研究(n=570),共937例危重成人脓毒症患者,其中543例接受辅助治疗性血浆置换。荟萃分析纳入全部5项RCT和仅6项匹配队列研究(n=627),辅助治疗性血浆置换组(n=300)较单纯标准治疗组(n=327)短期死亡率显著降低(RR 0.59,95%CI 0.47-0.74,I² 3%)。全部20项试验的系统评价显示,在标准治疗基础上加用治疗性血浆置换可使危重脓毒症患者的临床和/或实验室恢复更快。作者结论认为辅助治疗性血浆置换可能带来生存获益,但广泛采纳前需大型设计良好的随机试验确定最佳患者人群和血浆置换操作特征。

要点

  • 荟萃分析纳入5项RCT和6项匹配队列研究共627例,辅助治疗性血浆置换组(n=300)较单纯标准治疗组(n=327)短期死亡率降低(RR 0.59,95%CI 0.47-0.74,I² 3%)。
  • 系统评价共纳入20项试验937例危重成人脓毒症患者,其中543例接受辅助治疗性血浆置换。
  • 全部20项试验的系统评价显示,标准治疗加用治疗性血浆置换可使危重脓毒症患者的临床和/或实验室恢复更快。
  • 作者认为辅助治疗性血浆置换可能为脓毒症诱导器官功能障碍的危重成人带来潜在生存获益,但广泛采纳前需大型设计良好的随机试验确定最佳患者人群和血浆置换操作特征。

适用人群与场景

  • 危重成人脓毒症患者,伴脓毒症诱导的器官功能障碍,接受标准治疗。

研究设计与关键结果

  • 系统评价纳入5项随机对照试验(n=367)和15项匹配队列研究(n=570),共937例危重成人脓毒症患者,其中543例接受辅助治疗性血浆置换。
  • 荟萃分析纳入全部5项RCT和仅6项匹配队列研究(n=627):辅助治疗性血浆置换组(n=300)较单纯标准治疗组(n=327)短期死亡率显著降低(RR 0.59,95%CI 0.47-0.74,I² 3%)。
  • 全部20项试验的系统评价显示,在标准治疗基础上加用治疗性血浆置换可使危重脓毒症患者的临床和/或实验室恢复更快。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入随机对照试验和匹配队列研究。
  • 偏倚风险评估:RCT使用Cochrane协作工具,匹配队列研究使用ROBINS-I工具。
  • 统计方法:采用随机效应模型计算风险比(RR)和置信区间(CI)。
  • 局限:作者指出广泛采纳前需大型设计良好的随机试验确定最佳患者人群和血浆置换操作特征。

对床旁实践的改变

  • 作者认为辅助治疗性血浆置换可能为脓毒症诱导器官功能障碍的危重成人带来潜在生存获益,但广泛采纳前需大型设计良好的随机试验确定最佳患者人群和血浆置换操作特征。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: The impact of therapeutic plasma exchange (TPE) on short-term mortality in adult patients with sepsis-induced organ dysfunction remains uncertain. The objective of the study is to assess the effect of adjunct TPE in this setting through a comprehensive literature review.

METHODS: The National Library of Medicine's Medline, Ovid (Embase), the Cochrane Library database and clinicaltrial.gov from January 01, 1966, until October 01, 2022, were searched for terms: therapeutic plasma exchange, plasmapheresis, sepsis, and septic shock. We reviewed, selected and extracted data from relevant randomized clinical trials (RCTs) and matched cohort studies (MCSs) comparing short-term mortality in critically ill adult septic patients treated with standard therapy versus those receiving adjunct TPE. Risk of bias was assessed in the RCTs using Cochrane Collaboration tool and in MCSs using ROBINS-I tool. Summary statistics, risk ratios (RRs), and confidence intervals (CIs) were calculated using random effects model.

RESULTS: This systematic review included 937 adult critically ill septic patients from five RCTs (n = 367) and fifteen MCSs (n = 570). Of these total, 543 received treatment with TPE in addition to standard care. The meta-analysis includes all five RCTs and only six MCSs (n = 627). The adjunct TPE treatment (n = 300) showed a significant reduction in short-term mortality (RR 0.59, 95% CI 0.47-0.74, I2 3%) compared to standard therapy alone (n = 327). The systematic review of all 20 trials revealed that adding TPE to the standard therapy of critically ill septic patients resulted in faster clinical and/or laboratory recovery.

CONCLUSIONS: Our comprehensive and up-to-date review demonstrates that adjunct TPE may provide potential survival benefits when compared to standard care for critically ill adult patients with sepsis-induced organ dysfunction. While results of this meta-analysis are encouraging, large well-designed randomized trials are required to identify the optimal patient population and TPE procedure characteristics prior to widespread adoption into practice.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Kuklin V, Sovershaev M, Bjerner J, et al. Influence of therapeutic plasma exchange treatment on short-term mortality of critically ill adult patients with sepsis-induced organ dysfunction: a systematic review and meta-analysis. Crit Care. 2024. PMID: 38178170. doi:10.1186/s13054-023-04795-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。